Healthcare stocks finished down on Wall Street today, down 2.4%. More broadly, the Dow Jones Industrial Average fell 2.1%, the Nasdaq was down 2.4% and the S&P 500 declined 2.1%. Some of the biggest losers among healthcare stocks include: Acadia ...
Investor Place · 1 day ago
Healthcare Stocks
Check out some of the top losing stocks in the healthcare sector today: Acadia Pharmaceuticals Inc (ACAD)- The company’s shares dropped 4.9 pct. Abbvie Inc. Common Stock (ABBV)- The company’s stocks
Fx Pips · 1 day ago
As a brief example, Acadia Pharmaceuticals (NASDAQ: ACAD) was a beaten down biotech stock at one point because its experimental Parkinson's disease psychosis drug, Nuplazid, failed to meet its primary endpoint …
The Motley Fool · 2 hours ago
Biotech Investors
More from Bing News
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 0.14% on Thursday, hitting $42.76. 615,801 shares of the company’s stock traded hands. ACADIA Pharmaceuticals has a 52 week low of $19.21 and a 52 week high of $46.48. The …
Ticker Report · 6/25/2015
ACADIA Pharmaceuticals
Zacks now has a $9.00 price target on that stock. Finally, Zacks downgraded shares of Daimler AG from a strong-buy rating to a hold rating. ACADIA Pharmaceuticals (NASDAQ:ACAD) opened at 41.93 on Thursday. ACADIA Pharmaceuticals has a … · 6/27/2015
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) have received an average recommendation of “Buy” from the eleven analysts that are presently covering the company, Analyst Ratings.Net reports. One equities research analyst has rated the stock · 6/21/2015
One of today's stocks on the move is Acadia Pharmaceuticals (NASDAQ:ACAD), up 3.1% to $41.08. The Dow Jones Industrial Average is now trading 0.3% higher to 17,652 and the S&P is trading 0.3% higher to 2,065. Over the past year, Acadia …
Financial News Network Online · ByRobert Cotter · 22 hours ago
ACADIA Pharmaceuticals (NASDAQ:ACAD) has been given an average rating of “Buy” by the eleven brokerages that are currently covering the company, Analyst Ratings reports. One analyst has rated the stock with a sell recommendation …
Mideast Times · 6/18/2015
Halvorsen bought one biotechnology stock in addition to Esperion in the first quarter, ProQR Therapeutics NV (PRQR). He sold out of three other positions in the sector: Shire PLC (SHPG), ACADIA Pharmaceuticals Inc.
Yahoo Finance · 1 day ago
Regardless, one stock that has the potential to outperform the ETF in the next few years is ACADIA Pharmaceuticals (NASDAQ:ACAD). It has been 20 months since I published my report on ACADIA Pharmaceuticals, and made a bold call that sales of its …
Seeking Alpha · ByBrian Nichols · 6/22/2015